Compare Vertex Pharmaceuticals Incorporated (VRTX) vs ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. (ZTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. — how do they compare? Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B), while ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. trades at $20.1 (market cap $14.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 8.7× ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share.'s market cap, and ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. pays a 3.48% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VRTX | ZTO | |
|---|---|---|
Market Cap | $128.16B | $14.79B |
Volume | 806,603 | 1,618,264 |
Sector | Health | Industrials |
52-Week High | $557.96 | $25.88 |
52-Week Low | $407.37 | $18.50 |
Typical Hold Time | 120 Days | — |
Enterprise Value | $122.29B | $13.41B |
Dividend Yield | — | 3.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share.
ZTO Express provides domestic and international express delivery services in China. Its network-partner model combines ZTO's sorting and trunk transportation with partners' pickup and last-mile delivery.
Read more on ZTO →
